Paper Details

  1. Home
  2. Paper Details

[Efficacy of TAS-102].

Author: FukuokaShota, KotaniDaisuke, YoshinoTakayuki

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article discusses the drug TAS-102, a chemotherapeutic agent for treating metastatic colorectal cancers. The article highlights the “drug lag” phenomenon in Japan, where drug approval is often delayed compared to other regions. TAS-102, initially halted in US trials, was approved in Japan first after showing positive results in phase I and II clinical trials. The article summarizes the efficacy and side effects of TAS-102 based on data from various clinical trials.
Paper Details　
Original Abstract of the Article :
Of late, there has been rapid development of chemotherapeutic agents for treating metastatic colorectal cancers. However, the so-called "druglag" is a long-standingproblem; it refers to the drugapproval delays in Japan that occur after drugs have been developed and approved in Europe and the USA. Cl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/25596673

データ提供：米国国立医学図書館（NLM）

TAS-102: A Promising New Treatment for Metastatic Colorectal Cancer

The battle against metastatic colorectal cancer is a relentless endeavor, demanding innovative approaches and new therapeutic solutions. This research focuses on TAS-102, a novel chemotherapeutic agent, and its efficacy in treating this challenging disease. The authors highlight the positive results from Phase II clinical trials conducted in Japan and the subsequent global Phase III RECOURSE trial, which further confirmed the efficacy of TAS-102. This study offers hope for patients battling metastatic colorectal cancer, providing a new oasis of treatment options in the face of this challenging disease.

A New Oasis in the Desert of Cancer Treatment

This research offers a glimmer of hope for patients battling metastatic colorectal cancer, highlighting the potential of TAS-102 as a valuable treatment option. The study's findings suggest that TAS-102 may offer significant benefits for patients facing this challenging disease, potentially improving their chances of survival and quality of life.

Navigating the Complex Terrain of Cancer Treatment

This study underscores the importance of seeking out new and effective treatment options for metastatic colorectal cancer. The research highlights the potential of TAS-102 as a valuable tool for managing this challenging disease, offering hope for a brighter future for those navigating the complex terrain of cancer treatment.

Dr.Camel's Conclusion

This research reminds us that the journey to conquer cancer is far from over. The study's findings suggest that TAS-102 may offer a viable treatment option for patients battling metastatic colorectal cancer, potentially providing a new avenue for improved outcomes. This research serves as a reminder that the desert of cancer treatment is a challenging but rewarding landscape, where new and innovative solutions continue to emerge.

Date :
  1. Date Completed 2015-04-30
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

25596673

DOI: Digital Object Identifier

25596673

Related Literature

Article Analysis
・Side Effects of trifluridine and tipiracil
SNS
PICO Info
in preparation
Languages

Japanese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.